BETOPTIC PILO
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BETOPTIC PILO by Alcon is clinical pharmacology betaxolol hydrochloride, a cardioselective (beta 1 ) adrenoceptor antagonist, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Approved for elevated intraocular pressure in patients with primary open-angle glaucoma, ocular hypertension. First approved in 1997.
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETOPTIC PILO is a fixed-combination ophthalmic suspension combining betaxolol (a cardioselective beta-blocker) and pilocarpine (a cholinergic agent) for topical ocular use. It treats elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension by dual mechanisms: betaxolol decreases aqueous humor production while pilocarpine increases aqueous humor outflow. The combination provides 1-3 mmHg additional IOP lowering over betaxolol monotherapy when dosed three times daily.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, suggesting reduced team investment and focus on transition planning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Betaxolol hydrochloride, a cardioselective (beta 1 ) adrenoceptor antagonist, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic blocking agents reduce cardiac output…
Indications (2)
Worked on BETOPTIC PILO at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.